PMCB — Pharmacyte Biotech Income Statement
0.000.00%
Last trade - 00:00- $49.03m
- $34.77m
- 48
- 59
- 26
- 40
Annual income statement for Pharmacyte Biotech, fiscal year end - April 30th, USD millions except per share, conversion factor applied.
2021 April 30th | 2022 April 30th | 2023 April 30th | 2024 April 30th | 2025 April 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 3.55 | 4.39 | 6.46 | 8.52 | 4.38 |
| Operating Profit | -3.55 | -4.39 | -6.46 | -8.52 | -4.38 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -3.55 | -4.24 | -4.32 | 0.334 | 30.7 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -3.55 | -4.24 | -4.32 | 0.334 | 30.7 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -3.55 | -4.24 | -4.32 | 0.334 | 30.7 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -3.55 | -4.24 | -4.32 | -17.2 | 23.4 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.5 | -0.273 | -0.221 | -1.43 | 3.46 |